Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

Key Takeaway: NeuroPace, Inc. announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, set for September 28, 2023, in New York City. During the conference, the company will engage in a fireside chat, discussing its innovative RNS System designed to treat epilepsy. A live webcast of the discussion will be available, along with an archived replay for later access. NeuroPace focuses on transforming the lives of individuals suffering from drug-resistant epilepsy through its personalized treatment solutions.
Price reaction · baseline $8.35 (2023-09-19 close) · hit after-hours · clean, no other NPCE news in the window
day 0 close
-5.4%
day 1 · peak
-6.6%
day 3
-3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference showcases company visibility.
  • NeuroPace's innovative RNS System addresses a critical need for epilepsy treatment.
  • The company aims to improve patient outcomes with personalized solutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York.
A live webcast of the Cantor Fitzgerald discussion can be accessed through the Events & Presentations section of the Company’s website at investors.neuropace.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 90 days.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When is NeuroPace participating in the Cantor Fitzgerald Conference?

NeuroPace will participate in the Cantor Fitzgerald Conference on September 28, 2023, at 1:15 p.m. ET.

How can I access the NeuroPace webcast?

The webcast can be accessed through the Events & Presentations section of NeuroPace's website.

What is NeuroPace focused on?

NeuroPace focuses on transforming the lives of people living with epilepsy.

What is the RNS System offered by NeuroPace?

The RNS System is a brain-responsive platform that delivers real-time treatment for seizures.

How long will the webcast replay be available?

The archived replay of the webcast will be available for approximately 90 days.

Last updated: Sep 20, 2023